Programmed Intermittent Epidural Bolus Compared With Continuous Infusion in Multiparous Women
Launched by HOLY FAMILY HOSPITAL, NAZARETH, ISRAEL · Aug 26, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of providing pain relief during labor for women who have given birth before (multiparous women). The researchers want to find out if a technique called programmed intermittent epidural bolus, where women receive a dose of pain relief medication every hour, is more effective at reducing sudden pain (called breakthrough pain) compared to a continuous infusion, where the same medication is given steadily over time until delivery.
To participate in the trial, women must meet specific criteria. They should be at term in their pregnancy (meaning they are close to their due date), having a single baby that is positioned head-down, and should be in the early stages of labor (with less than 6 cm of cervical dilation). They also need to request epidural pain relief and have a pain level that is significant. If you or someone you know is eligible and decides to participate, they will either receive the hourly bolus method or the continuous infusion method during labor. This trial is currently recruiting participants, and it aims to improve how pain is managed during childbirth.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. multiparous women
- • 2. Term pregnancy
- • 3. Singleton
- • 4. Vertex presentation
- • 5. Latent phase (cervical dilatation less than 6 cm)
- • 6. Epidural analgesia request
- • 7. Visual Analogue Scale score greater than 40
- Exclusion Criteria:
- • 1. Estimated fetal weight greater than 4.0 kg
- • 2. Intra uterine fetal death
- • 3. Drug sensitivity
- • 5. Anomalous fetus 6. Contraindication for epidural analgesia
About Holy Family Hospital, Nazareth, Israel
Holy Family Hospital, located in Nazareth, Israel, is a prominent healthcare institution dedicated to providing high-quality medical services and advancing clinical research. As a clinical trial sponsor, the hospital is committed to enhancing patient care through innovative research initiatives that explore new treatments and therapies. With a focus on patient safety and ethical standards, Holy Family Hospital collaborates with healthcare professionals and researchers to contribute valuable insights to the medical community, ultimately aiming to improve health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nazareth, , Israel
Nazareth, , Israel
Patients applied
Trial Officials
Raed Salim, MD
Study Chair
Holy Family Hospital, Nazareth, Israel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported